MX2023005273A - Composiciones farmaceuticas de un inhibidor de cinasa. - Google Patents

Composiciones farmaceuticas de un inhibidor de cinasa.

Info

Publication number
MX2023005273A
MX2023005273A MX2023005273A MX2023005273A MX2023005273A MX 2023005273 A MX2023005273 A MX 2023005273A MX 2023005273 A MX2023005273 A MX 2023005273A MX 2023005273 A MX2023005273 A MX 2023005273A MX 2023005273 A MX2023005273 A MX 2023005273A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
kinase inhibitor
relates
modulating
disorder
Prior art date
Application number
MX2023005273A
Other languages
English (en)
Spanish (es)
Inventor
Iswadi Liejanto
Tzu-Yuan Chen
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2023005273A publication Critical patent/MX2023005273A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023005273A 2020-11-05 2021-11-04 Composiciones farmaceuticas de un inhibidor de cinasa. MX2023005273A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063110124P 2020-11-05 2020-11-05
PCT/US2021/057996 WO2022098828A1 (en) 2020-11-05 2021-11-04 Pharmaceutical compositions of a kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2023005273A true MX2023005273A (es) 2023-05-23

Family

ID=78820880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005273A MX2023005273A (es) 2020-11-05 2021-11-04 Composiciones farmaceuticas de un inhibidor de cinasa.

Country Status (16)

Country Link
US (1) US20230398108A1 (enExample)
EP (1) EP4240333A1 (enExample)
JP (1) JP2023548855A (enExample)
KR (1) KR20230104186A (enExample)
CN (1) CN116406261A (enExample)
AU (1) AU2021374669A1 (enExample)
CA (1) CA3196001A1 (enExample)
CL (1) CL2023001268A1 (enExample)
CO (1) CO2023005942A2 (enExample)
CR (1) CR20230223A (enExample)
GE (1) GEAP202316262A (enExample)
IL (1) IL302485A (enExample)
MX (1) MX2023005273A (enExample)
PE (1) PE20240223A1 (enExample)
TW (1) TW202227061A (enExample)
WO (1) WO2022098828A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202415420A (en) * 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009722A1 (en) * 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
US11564915B2 (en) * 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
GEAP202415420A (en) 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP4631505A3 (en) 2018-12-13 2025-12-10 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
US20220072002A1 (en) * 2018-12-24 2022-03-10 Chia Tai Tianqing Pharmaceuticalgroup Co., Ltd. Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound

Also Published As

Publication number Publication date
PE20240223A1 (es) 2024-02-16
JP2023548855A (ja) 2023-11-21
WO2022098828A1 (en) 2022-05-12
CL2023001268A1 (es) 2023-12-11
CA3196001A1 (en) 2022-05-12
CR20230223A (es) 2023-07-07
CO2023005942A2 (es) 2023-05-19
EP4240333A1 (en) 2023-09-13
TW202227061A (zh) 2022-07-16
KR20230104186A (ko) 2023-07-07
AU2021374669A9 (en) 2024-04-18
CN116406261A (zh) 2023-07-07
IL302485A (en) 2023-06-01
GEAP202316262A (en) 2023-08-10
US20230398108A1 (en) 2023-12-14
AU2021374669A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
PH12021551019A1 (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
PH12021551356A1 (en) Crystalline forms and salt forms of a kinase inhibitor
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
MY209609A (en) Immunomodulators, compositions and methods thereof
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MX2021015874A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
UA103617C2 (ru) Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
PH12022553019A1 (en) Il-17a modulators
ZA202108034B (en) Crystalline salt forms of a kinase inhibitor
EP4374928A3 (en) Novel alk2 inhibitors and methods for inhibiting bmp signaling
CL2023001268A1 (es) Composiciones farmacéuticas de un inhibidor de cinasa
PH12022500021A1 (en) Il-17a modulators
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
EP2124990A4 (en) TUMOR TREATMENT BASED ON ROMIDEPSIN
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2024009216A (es) Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
ZA202400821B (en) Inhibitors of transglutaminases
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
MX2024014435A (es) Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
MX2024014831A (es) Derivados de acido sialico y metodos de uso de los mismos
MX2023015096A (es) Inhibidores de transglutaminasas.